Condition
Refractory/Relapse Acute Myeloid Leukemia clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Refractory/Relapse Acute Myeloid Leukemia clinical trials that are recruiting, at sites in 2 countries (most in China (1), United States (1)). By phase: Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
Allogeneic CAR-T CT0890B for relapsed/refractory AML
This study tests whether a universal CAR-T cell therapy called CT0890B is safe and potentially effective for adults with relapsed or refractory acute myeloid leukemia who express NKG2D ligands.
-
C6 ceramide nanoliposome (CNL) treatment for relapsed or refractory acute myeloid leukemia
This will test whether C6 ceramide delivered in a nanoliposome (CNL) by IV is safe for adults whose acute myeloid leukemia has relapsed or not responded to prior treatment.
Related topics
Quick answers
How many Refractory/Relapse Acute Myeloid Leukemia clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.